TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
VTGN

VistaGen Therapeutics Inc

Healthcare · Biotechnology

0.2336$ +1.3% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns VistaGen Therapeutics Inc (VTGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.3% of the shares are freely tradable; institutional investors hold 40.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 40.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 93.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 44Mio.

Largest Shareholders

Institutions

Institutions VTGN
Name Stake (%) Shares Change (%) Date
Orbimed Advisors LLC 6.90 3,060,000 +0.0 03/31/2026
Vanguard Capital Management, LLC 3.55 1,574,200 +0.0 03/31/2026
StemPoint Capital LP 2.78 1,233,498 +100.0 03/31/2026
Two Sigma Investments LLC 1.91 847,992 +80.6 06/30/2026
ADAR1 Capital Management LLC 1.69 751,141 +20.5 03/31/2026
Acadian Asset Management LLC 1.33 589,663 +0.0 03/31/2026
Ikarian Capital, LLC 1.17 519,077 +0.0 03/31/2026

Funds

Funds VTGN
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.62 1,160,455 +0.0 07/31/2026
Biotech Growth Ord 1.82 808,700 +0.0 05/31/2026
AdvisorShares Psychedelics ETF 1.18 525,149 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?